Bijal J. Shah, MD
In March 2017, tisagenlecleucel-T (CTL019) became the first chimeric antigen receptor (CAR) T-cell therapy to enter regulatory review when the FDA granted the treatment a priority review for use as a treatment for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia (ALL).
In an interview with OncLive, Shah discussed the significant impact CAR T-cell therapy can have on the treatment landscape for patients with ALL.
OncLive: Can you provide an overview of your presentation at this meeting?
I wanted to summarize the work that’s been done across the clinical trials in adult ALL. We will hopefully see our first approval in pediatric ALL sometime this year since the data has been submitted to the FDA and is currently under review.
... to read the full story